TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail
This is a Phase III, a randomized, double-blind, parallel , multi-center trail to evaluate the efficacy and safety of TQB3616 capsules plus fulvestrant compared to placebo plus fulvestrant in participants with estrogen receptor-positive, HER2-Negative Advanced Breast Cancer. Approximately 287 women will be randomized to either TQB3616 plus fulvestrant or TQB3616-matching placebo plus fulvestrant. Randomization will follow a 2:1 randomization ratio,the experimental is 191; the Placebo Comparator is 96.
HR-positive,HER2-negative in Advanced Breast Cancer
DRUG: TQB3616 capsules|DRUG: TQB3616-matching placebo|DRUG: Fluvestrin injection
Progression-free survival (PFS), Progression-free survival (First-time progression of disease/ recurrence /death), Baseline up to 24 months
Progression-free survival (PFS) by Independent Review Committee, Progression-free survival（First-time progression of disease/ recurrence /death）, Baseline up to 24 months|Overall survival (OS), Overall survival (Baseline up to death), Baseline up to 24 months|Clinical benefit rate (CBR), Percentage of subjects with complete (CR) or partial response (PR) or stable disease (SD)（ Baseline up to progression of disease/ recurrence /death）, Baseline up to 24 months|Duration of Response (DOR), Duration of Response(Baseline up to progression of disease/ recurrence /death), Baseline up to 24 months
This is a Phase III, a randomized, double-blind, parallel , multi-center trail to evaluate the efficacy and safety of TQB3616 capsules plus fulvestrant compared to placebo plus fulvestrant in participants with estrogen receptor-positive, HER2-Negative Advanced Breast Cancer. Approximately 287 women will be randomized to either TQB3616 plus fulvestrant or TQB3616-matching placebo plus fulvestrant. Randomization will follow a 2:1 randomization ratio,the experimental is 191; the Placebo Comparator is 96.